Atlas Trials

Safety Study of Anti-IgE Immunotherapy in Allergic Patients

Clinical trial NCT00439621 · COMPLETED

Trial details

NCT number
NCT00439621
Sponsor
Resistentia Pharmaceuticals AB
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Allergy
Start date
2007-02-01
Primary completion
2008-03-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.